In Phase 5, which populations might be studied?

• A. Only healthy volunteers.
• B. Only patients with the intended indication.
• C. Special populations such as elderly, pediatric, or renal-impaired patients.
• D. Only animals.

Answer: (C)

In Phase 5, the focus is on post-approval, real-world safety and effectiveness across a broad and diverse group of people. This stage is about monitoring how a drug performs beyond the controlled settings of earlier trials, including special populations who may have different pharmacokinetics or risks. Elderly patients, children, and those with renal impairment are prime examples because age-related changes, developmental differences, and reduced kidney function can alter drug clearance and handling. Phase 5 studies look for rare or long-term adverse effects, drug–drug interactions in polypharmacy, and how the medicine is used in everyday practice, often guiding labeling updates and safer-use recommendations.

Healthy volunteers are typical of early-phase work, where the emphasis is on basic safety and pharmacokinetics in people without disease. Trials limited to patients with only the intended indication occur earlier in the development path (though they may continue in Phase 3). Animal studies are preclinical, occurring before human trials.